The Week in Review: WuXi AppTec and MedImmune Start Joint Venture

WuXi AppTec and MedImmune, an AstraZeneca subsidiary, formed a JV that will develop a MedImmune anti-inflammatory mAb for China commercialization; 3SBio, a Shenyang biotech, received an offer from its Chairman and a CITIC entity to take the company private at a price of $15 per ADS; two high-visibility generic drug JVs – Hisun-Pfizer and Merck-Simcere – began operations after a year of preparation; Qiagen teamed up with Lepu Medical Technology (Beijing) to offer cardiac diagnostic tests; and Generon (Shanghai) Corporation started a Phase I clinical trial in Australia of a novel anti-inflammatory drug candidate. More details…. Stock Symbols: (NYSE: WX) (NYSE: AZN) (NSDQ: SSRX) (SHE: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE SCR) (NSDQ: QGEN) (SHE: 300003) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});